]>
IRCT20100314003566N10 IRCT 2020-03-04 Tabriz University of Medical Sciences Triamcinolone Acetonid in Alopecia Areata Comparative Efficacy of Different Concentrations of Triamcinolone Acetonid in Alopecia Areata 2020-01-07 anticipated 45 Complete https://irct.ir/trial/42025 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: not to use, Randomization description: Patients were randomly selected using a sealed envelope. The letters A, B and C will be used in the envelopes, and none of the study members will be aware of the contents of the envelopes, Blinding description: The drug will be injected in all specimens at different doses and in all specimens with more than one lesion; if there is a lesion more than 3 cm away from the central lesion at which the drug is injected, The face will be blind as a placebo injection. 3 Alopecia Areata. Intervention 1: Intervention group 1: Intra-lesional injection of triamcinolone acetonide with a dose of 2.5 mg/ml. Intervention 2: Intervention group 2: Intra-lesional injection of triamcinolone acetonide with a dose of 5 mg/ml. Intervention 3: Intervention group 3: Intra-lesional injection of triamcinolone acetonide with a dose of 10 mg/ml. Yes - There is a plan to make this available What will be shared: All data will be shared after being unidentified. When: At any time To whom: It will be free for everyone Conditions: There are no special conditions Where to obtain: Email:azimi@tbzmed.ac.ir , Dr Hamideh Azimi 09141168015, Dermatology Department- Sina Hospital- Azadi Street- Tabriz. How to obtain: The Request will be checked, then data will be sent by Email in 1 month. Comments:
public Hamideh Azimi Alamdari
between Montazeri and Hafez crossroad, Azadi Street, Sina Hospital
Tabriz Iran (Islamic Republic of) 5163639888 +98 41 3541 2101 azimi@tbzmed.ac.ir Tabriz University of Medical Sciences scientific Hamideh Azimi Alamdari
between Montazeri and Hafez crossroad, Azadi Street, Sina Hospital
Tabriz Iran (Islamic Republic of) 5163639888 +98 41 3541 2101 azimi@tbzmed.ac.ir Tabriz University of Medical Sciences Iran (Islamic Republic of) Alopecia areata patients with one or more patch lesions. Patients 15 years and older Patients who declare their full consent to participate in the study. The duration of the disease is 3 to 12 months and there is no sign of new hair growth at the site of the lesion. 15 years no limit Both Children Background or presence of skin diseases such as psoriasis, seborrheic dermatitis, and malignancy and infection at the site Patients with malignancy and blood dyscrasia Pregnant and lactating women Patients with mental retardation and physical disability Patients who have received topical or systemic corticosteroids and topical treatments in alopecia areata or immunosuppressive drugs over the past month. People with autoimmune, type I diabetes, etc. No seizure L63.8 Other alopecia areata Treatment - Drugs Treatment - Drugs Treatment - Drugs Intervention group 1: Intra-lesional injection of triamcinolone acetonide with a dose of 2.5 mg/ml. Intervention group 2: Intra-lesional injection of triamcinolone acetonide with a dose of 5 mg/ml. Intervention group 3: Intra-lesional injection of triamcinolone acetonide with a dose of 10 mg/ml. Number and Length of new hear at lesion site. Timepoint: Monthly. Method of measurement: Clinical Examination of Number and Length of new hear at lesion site. New Hear Growth Rate. Timepoint: Monthly. Method of measurement: Clinical Examination of New Hear Growth Rate on Injection Site. Tabriz University of Medical Sciences Approved 2020-01-06 Ethics committee of Tabriz University of Medical Sciences Golgasht Ave., Azadi St., Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)